Viridian Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Viridian Therapeutics Inc in the first quarter 2026?
Viridian Therapeutics Inc recorded a cumulative net loss of $-371 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -60.16%.

Within the Medical Laboratories industry 25 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2025 from 2340 to 2894.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	-5.31 %	2.07 %	-4.98 %	3.77 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-371	-346	-278	-308	-270
Return On Equity (TTM)	-60.16 %	-55.27 %	-44.71 %	-49.08 %	-43.35 %
VRDN's Total Ranking	# 2894	# 2340	# 1104	# 3031	#
Equity (TTM) in Millions	636	722	503	604	672
Seq. Equity Change	-11.93 %	43.58 %	-16.79 %	-10 %	-5.07 %
Seq. Net Income Change	-	-	-	-	-

Back to VRDN Management Effectiveness >> VRDN's 5 Years Annual ROE >> Compare VRDN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 26
Sector	# 426
Overall	# 2894

Return On Equity Statistics
High	Average	Low
-43.35 %	-52.92 %	-68.31 %
(Dec 31 2024)		(Dec 31 2023)

VRDN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	722	672	442	395	188
Y / Y Equity Change	7.52 %	51.95 %	11.89 %	110.46 %	56.38 %
Net Income in Millions	-343	-270	-238	-130	-79
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-47.44 %	-40.19 %	-53.78 %	-32.87 %	-42.3 %

Back to VRDN Management Effectiveness >> VRDN's 5 Years Annual ROE >> Compare VRDN ROE to its Competitors

More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VRDN's' Return on Equity at Yahoo Finance
VRDN's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for VRDN's Competitors
Subscribers only: Roe for Viridian Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for VRDN's Customers

Companies with similar Return On Equity at Mar 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.